一、 回购股份的基本情况 2025 年 1 月 21 日，奥锐特药业股份有限公司（以下简称"公司"）召开第三 届董事会第十二次会议，会议以 9 票同意、0 票反对、0 票弃权审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式回 购公司股份，回购的股份全部用于转换公司可转债。本次回购股份的资金总额为 不低于人民币 6,000 万元（含），不高于人民币 12,000 万元（含），回购价格不超 过人民币 25.00 元/股（含），回购期限自公司董事会审议通过回购方案之日起不 超过 12 个月。 | | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 | 月 | 21 | 日~2026 | ...

Group 1 - The company Aorite (SH 605116, closing price: 23.69 CNY) announced on August 4 that as of July 31, 2025, it has repurchased a total of 1.4142 million shares through the Shanghai Stock Exchange trading system, accounting for 0.35% of the current total share capital, with a total expenditure of approximately 28.22 million CNY [2] - The highest repurchase price was 21.3 CNY per share, while the lowest was 18.83 CNY per share [2] Group 2 - For the year 2024, the revenue composition of Aorite is as follows: self-produced raw materials and intermediates accounted for 77.29%, formulations accounted for 14.91%, trade accounted for 7.55%, and other businesses accounted for 0.25% [2]

格隆汇8月4日丨奥锐特(605116.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以集 中竞价交易方式已累计回购公司股份141.42万股，占公司目前总股本的比例为0.35%，回购成交的最高 价为21.30元/股，最低价为18.83元/股，支付的资金总额为人民币28,220,158.00元（不含交易费用）。 ...

Group 1 - The core point of the article is that senior management personnel Zhao Zhenping of Aorite (605116.SH) plans to reduce his shareholding due to personal financial needs [1] - Zhao Zhenping intends to reduce his holdings by no more than 62,500 shares, which accounts for 0.02% of the company's total share capital [1] - The reduction will take place within three months after a 15 trading day period from the announcement date, during which no shares will be sold [1]

奥锐特8月4日公告，公司高级管理人员赵珍平因个人资金需求，计划自公告发布之日起15个交易日后的 3个月内，通过集中竞价方式减持公司股份不超过6.25万股，即不超过公司总股本的0.02%。减持价格将 根据减持实施时的市场价格确定。本次减持计划实施具有不确定性。 ...

Core Viewpoint - As of August 1, 2025, Aorite (605116) closed at 23.96 yuan, down 0.58%, with a turnover rate of 1.19% and a trading volume of 47,500 hands, resulting in a transaction amount of 114 million yuan [1] Trading Information Summary - On August 1, Aorite's capital flow indicated a net outflow of 5.71 million yuan from main funds, accounting for 5.0% of the total transaction amount [2][3] - Retail investors showed a net inflow of 7.87 million yuan, representing 6.88% of the total transaction amount [2] Company Announcement Summary - Aorite Pharmaceutical Co., Ltd. announced the redemption of part of its idle raised funds for cash management, allowing the use of up to 300 million yuan of idle raised funds, with a rolling usage limit valid for 12 months from the approval date of the third board meeting [2] - On June 30, 2025, the company invested 40 million yuan in a structured deposit product from Industrial Bank, which had a term from July 1 to July 31, 2025, and has since been redeemed, yielding a profit of 62,500 yuan [2][3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing up to RMB 300 million to be utilized within a 12-month period [1]. Group 1 - The company held its third board meeting on August 27, 2024, where it approved the cash management proposal [1]. - The approved amount for cash management is RMB 300 million, which can be rolled over within the specified timeframe [1]. - The management team is authorized to make decisions regarding the use of these funds, with the finance department responsible for implementation [1]. Group 2 - On June 30, 2025, the company used RMB 40 million of the idle funds to purchase structured deposit products from Industrial Bank [2]. - The structured deposit product has since been redeemed [2].